Matt Hoffman

Expert clinicians offer their perspectives on transitional care in pediatric MS, a biomarker for SUDEP, and a novel approach to narcolepsy, among other topics.

Karl Doghramji, MD, the medical director of the Jefferson Sleep Disorders Center at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health, looks ahead to the needs for sleep care heading into 2022.

In a NeurologyLive® Peer Exchange series, experts on the care of patients with multiple sclerosis offer recommendations for selecting and sequencing therapies used to treat patients with relapsing disease.

Aducanumab’s (Aduhelm; Biogen) $56,000 price point reflects the larger challenges of the United States’ insurance system and incites a cyclical series of events that have repercussions on cost of future therapies, state budgets, and legislative decisions.

The medical director of the Jefferson Sleep Disorders Center at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health offered his insight into the current state of care for sleep and the progress made this year.

The American Academy of Neurology’s statement touched on the roles played by the principles of beneficence, nonmaleficence, justice, and patient autonomy as it relates to the clinical use of the therapy for this patient population.

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Karl Doghramji, MD, FAASM, DFAPA.

Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, University of Michigan Medicine, spoke to the benefits of a multifaceted approach to managing fatigue for patients with multiple sclerosis.

Ivana Rubino, PhD, the head of Medical for Global Alzheimer at Biogen, offered her perspective on the recently presented data at CTAD 2021.

The data, which suggest that a lessened decline in cognition and function was correlated with a reduction in plasma p-tau181 levels in those with Alzheimer disease treated with aducanumab (Aduhelm; Biogen), were presented at CTAD 2021.

After Amylyx submitted an NDA for the combination therapy, Justin Klee and Josh Cohen, the cofounders and co-chief operating officers of the company, shared their perspectives.

Marisa McGinley, DO, offered her perspective on the use of telemedicine in the management of patients with MS, summarizing the benefits it provides and the challenges that remain as it is more increasingly incorporated into care.

Expert clinicians offer their perspectives on the ongoing shortage of neurologists, stigmas associated with migraine, diets for those with epilepsy, mesenchymal stem cells in MS, and other topics.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Victor Sung, MD.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

The Renew Biosciences device is designed to enhance circulation and improve cerebrovascular health by stimulating the physiological effects of exercise and the function of endothelial cells.

Mitchell S. V. Elkind, MD, MS, MPhil, shared his perspective and offered insights into the recent updates from the American Heart Association/American Stroke Association on the landscape of stroke prevention and poststroke care.

Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, and a research nonclinical psychologist, University of Michigan Medicine, offered insight into the multidisciplinary approach to managing fatigue for patients with multiple sclerosis.

The director of the Multiple Sclerosis Experimental Therapeutics Program at Johns Hopkins Medicine offered insight on the TREAT-MS trial to attendees of the CMSC 2021 annual meeting.

In the presidential lecture series at CMSC 2021, Ellen M. Mowry, MD, called into question whether or not the induction treatment approach in multiple sclerosis does in fact present a higher chance of preventing long-term disability.

Real-world data from a single-center study with more than 4 years of follow-up showed similar rates of moderate infections and malignancies to the general population with multiple sclerosis.

Both diets resulted in patients with MS reporting significant changes on Perceived Deficits Questionnaire scores for fatigue and cognitive dysfunction after 12 weeks of intervention.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Stephen Krieger, MD.

Despite projections that aducanumab (Aduhelm; Biogen) would be widely adopted in clinical practice after its June 2021 approval, financial reports suggest a different story. Jessica Zwerling, MD, MS, and Lon Schnider, MD, MS, offered their perspectives on its clinical application thus far.

Ashish Pradhan, MD, the executive director and disease area lead for MS and NMOSD, Genentech, offered insight on a number of presentations at the 2021 ECTRIMS Congress.

The authors noted that the CBT-acupressure approach may serve particularly well for individuals whose cultural values align with traditional Chinese medicine approaches.

In the final day’s plenary session at ECTRIMS Congress, Ruth Ann Marrie, MD, PhD, FRCPC, FCAHS, gave a look into some of the notable presentations from the annual meeting.

The vast majority of patients with MS, 63.4%, who initiated ofatumumab treatment in the 6 months after its approval had mild disability, while only 29.2% had moderate disability and 7.4% had severe disability.

In addition to the data presented at ECTRIMS Congress 2021, Atara Bio is investigating the therapy in an ongoing and enrolling phase 2 study, EMBOLD (NCT03283826), which is expected to read out interim results in early 2022.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Gregory W. Albers, MD.